MARKET

EXEL

EXEL

Exelixis Inc
NASDAQ
22.49
-0.38
-1.66%
After Hours: 22.44 -0.05 -0.22% 16:04 04/18 EDT
OPEN
23.00
PREV CLOSE
22.87
HIGH
23.23
LOW
22.46
VOLUME
2.61M
TURNOVER
0
52 WEEK HIGH
24.34
52 WEEK LOW
18.08
MARKET CAP
6.82B
P/E (TTM)
34.80
1D
5D
1M
3M
1Y
5Y
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
Exelixis, Inc. Will release its first quarter 2024 financial results on April 30, 2024 after the markets close. The company will host a conference call and webcast to discuss the results and provide a business update. The event will be available via the Internet from the company's website.
Barchart · 2d ago
Weekly Report: what happened at EXEL last week (0408-0412)?
Weekly Report · 4d ago
Exelixis slips as Barclays downgrades on lack of catalysts
Barclays downgrades cancer drugmaker Exelixis on lack of catalysts. Lead asset cabozantinib faces a patent cliff, analyst says. Barclays sees better upside potential in other companies with similar pipelines. Exelxis shares traded lower on Thursday.
Seeking Alpha · 04/11 14:10
Exelixis Cut to Equal-Weight From Overweight by Barclays
Dow Jones · 04/11 13:05
Exelixis Price Target Maintained With a $25.00/Share by Barclays
Dow Jones · 04/11 13:05
Barclays Downgrades Exelixis to Equal-Weight, Maintains Price Target to $25
Benzinga · 04/11 12:55
EXELIXIS INC <EXEL.O>: BARCLAYS CUTS TO EQUAL WEIGHT FROM OVERWEIGHT
Reuters · 04/11 10:56
U.S. RESEARCH ROUNDUP-Airbnb, Albemarle, Biogen
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Airbnb, Albemarle and Biogen among those with revised targets. AIG, Aflac and Allstate among companies with new targets for the day. Analysts cut target prices on some of the companies.
Reuters · 04/11 07:32
More
About EXEL
Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Webull offers Exelixis Inc stock information, including NASDAQ: EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.